pre-IPO PHARMA

COMPANY OVERVIEW

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock’s Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock’s cell differentiation technology recapitulates the cell’s developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.


LOCATION

  • Toronto, Ontario, Canada
  • New York, NY, USA
  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Cardiovascular Disease
  • Neurodegenerative Disease

  • WEBSITE

    https://bluerocktx.com/


    CAREER WEBSITE

    https://bluerocktx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    bayer versant-ventures


    PRESS RELEASES


    Jul 19, 2021

    BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease


    Jun 8, 2021

    BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease


    May 17, 2021

    BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic RandD Alliance to Discover and Develop Cell Therapies for Eye Diseases


    Apr 7, 2021

    BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease


    Jan 7, 2021

    BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease


    For More Press Releases


    Google Analytics Alternative